Logo Logo

Hölz, Hannes; Heetmeyer, Jeannine; Tsakmaklis, Anastasia; Hiergeist, Andreas; Siebert, Kolja; De Zen, Federica; Häcker, Deborah; Metwaly, Amira; Neuhaus, Klaus; Gessner, Andre; Vehreschild, Maria J.G.T.; Haller, Dirk; Schwerd, Tobias (2023): Is Autologous Fecal Microbiota Transfer after Exclusive Enteral Nutrition in Pediatric Crohn’s Disease Patients Rational and Feasible? Data from a Feasibility Test. Nutrients, 15: 1742. ISSN 2072-6643

[thumbnail of nutrients-15-01742.pdf] Veröffentlichte Publikation
nutrients-15-01742.pdf

Die Publikation ist unter der Lizenz Creative Commons Namensnennung (CC BY) verfügbar.

Herunterladen (2MB)

Abstract

Background: Exclusive enteral nutrition (EEN) is a highly effective therapy for remission induction in pediatric Crohn’s disease (CD), but relapse rates after return to a regular diet are high. Autologous fecal microbiota transfer (FMT) using stool collected during EEN-induced clinical remission might represent a novel approach to maintaining the benefits of EEN. Methods: Pediatric CD patients provided fecal material at home, which was shipped at 4 °C to an FMT laboratory for FMT capsule generation and extensive pathogen safety screening. The microbial community composition of samples taken before and after shipment and after encapsulation was characterized using 16S rRNA amplicon sequencing. Results: Seven pediatric patients provided fecal material for nine test runs after at least three weeks of nutritional therapy. FMT capsules were successfully generated in 6/8 deliveries, but stool weight and consistency varied widely. Transport and processing of fecal material into FMT capsules did not fundamentally change microbial composition, but microbial richness was <30 genera in 3/9 samples. Stool safety screening was positive for potential pathogens or drug resistance genes in 8/9 test runs. Conclusions: A high pathogen burden, low-diversity microbiota, and practical deficiencies of EEN-conditioned fecal material might render autologous capsule-FMT an unsuitable approach as maintenance therapy for pediatric CD patients.

Publikation bearbeiten
Publikation bearbeiten